Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of Sipagladenant (KW-6356) in Healthy Men
NCT04147910Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Aug 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sipagladenant in Parkinson's disease (PD), sponsored by Kyowa Kirin. Primary endpoints: Maximum Plasma Concentration (Cmax), Time to Maximum Concentration (tmax) and 12 more. Started Aug 2019; status: completed.
02
Drugs
sipagladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04147910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147910.